Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized platform study of targeted therapies for adults with moderate to severe Crohn's disease
MOH_2024-09-11_013635Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of risankizumab, ABBV-382 and lutikizumab in Crohn's disease (6 arms), sponsored by AbbVie Inc. Started Sep 2024; status: recruiting.
02
Drugs
risankizumabABBV-382lutikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2024-09-11_013635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-11_013635.